Eye Health America

eyehealthamerica.com

Eye Health America partners with eye care practices and ambulatory surgery centers to provide superior clinical care. Our member practices offer full-service eye care from routine eye exams, contact lenses and glasses to medical ophthalmology and surgery including cataract, cornea, retina, glaucoma, pediatrics and oculoplastics. We support practice groups and ASCs as they grow locations and service offerings, enabling them to focus on delivering the highest quality outcomes and meeting a rapidly growing need for eye care. Visit www.eyehealthamerica.com to learn more.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Pharma Tech

ADDITIONAL US$ 4 MILLION RECEIVED FOR NEXT DEVELOPMENT STEPS OF MEDINCELL'S 6-MONTH ACTIVE INJECTABLE BIORESORBABLE SUBCUTANEOUS CONTRACEPTIVE

MedinCell | December 01, 2022

news image

MedinCell has received an additional US$ 4 million payment from the Bill & Melinda Gates Foundation This amount is intended to finance the next steps of MedinCell’s program mdc-WWM in readiness to initiate the first clinical trial end of 2023 It follows US$ 11,8 million already received as part of the two successive grants for a total of up to US$ 22,5 million from the Bill & Melinda Gates Foundation to finance the development of the program up to phas...

Read More

PHARMACY MARKET, PHARMA TECH

JAZZ PHARMACEUTICALS MAINTAINS EXCLUSIVE RIGHTS TO DEVELOP AND SELL ZYMEWORKS' ZANIDATAMAB

Jazz Pharmaceuticals plc and Zymeworks Inc. | December 28, 2022

news image

Jazz Pharmaceuticals plc and Zymeworks Inc. recently informed that the former has chosen to keep its exclusive rights to develop and sell Zymeworks' Zanidatamab in key markets, such as the U.S., Europe, and Japan, as part of the license and collaboration agreement made in October 2022. A pivotal trial in previously treated HER2-amplified biliary tract tumors (BTC) found that 41.3% (95% CI: 30.4, 52.8) of recruited patients with HER2-amplified and expressing (IHC2+ and 3+) illn...

Read More

CNS PHARMACEUTICALS ANNOUNCES US DRUG MANUFACTURING MILESTONES

CNS Pharmaceuticals | September 03, 2020

news image

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the central nervous system, today provides an update on progress for the U.S. manufacturing of Berubicin, the Company's lead drug candidate, in preparation for upcoming clinical trials. As previously announced, the Company implemented a dual-track drug product manufacturing strategy and eng...

Read More

Business Insights

ON DEMAND PHARMACEUTICALS ANNOUNCES PREFERRED SUPPLIER RELATIONSHIP WITH AZZUR GROUP

On Demand Pharmaceuticals, Azzur Group | June 02, 2022

news image

On Demand Pharmaceuticals, Inc. an innovative technology company transforming the way medicines are made, announced that it has signed a Preferred Supplier agreement with Azzur Group through 2024. The transformation of ODP's Rockville Headquarters into a State-of-the-Art cGMP Medicine Manufacturing facility began with Azzur in the fall of 2020. Azzur collaborated in designing ODP's GMP Roadmap and helped develop the strategy and execution plan for ushering in this latest a...

Read More
news image

Pharma Tech

ADDITIONAL US$ 4 MILLION RECEIVED FOR NEXT DEVELOPMENT STEPS OF MEDINCELL'S 6-MONTH ACTIVE INJECTABLE BIORESORBABLE SUBCUTANEOUS CONTRACEPTIVE

MedinCell | December 01, 2022

MedinCell has received an additional US$ 4 million payment from the Bill & Melinda Gates Foundation This amount is intended to finance the next steps of MedinCell’s program mdc-WWM in readiness to initiate the first clinical trial end of 2023 It follows US$ 11,8 million already received as part of the two successive grants for a total of up to US$ 22,5 million from the Bill & Melinda Gates Foundation to finance the development of the program up to phas...

Read More
news image

PHARMACY MARKET, PHARMA TECH

JAZZ PHARMACEUTICALS MAINTAINS EXCLUSIVE RIGHTS TO DEVELOP AND SELL ZYMEWORKS' ZANIDATAMAB

Jazz Pharmaceuticals plc and Zymeworks Inc. | December 28, 2022

Jazz Pharmaceuticals plc and Zymeworks Inc. recently informed that the former has chosen to keep its exclusive rights to develop and sell Zymeworks' Zanidatamab in key markets, such as the U.S., Europe, and Japan, as part of the license and collaboration agreement made in October 2022. A pivotal trial in previously treated HER2-amplified biliary tract tumors (BTC) found that 41.3% (95% CI: 30.4, 52.8) of recruited patients with HER2-amplified and expressing (IHC2+ and 3+) illn...

Read More
news image

CNS PHARMACEUTICALS ANNOUNCES US DRUG MANUFACTURING MILESTONES

CNS Pharmaceuticals | September 03, 2020

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the central nervous system, today provides an update on progress for the U.S. manufacturing of Berubicin, the Company's lead drug candidate, in preparation for upcoming clinical trials. As previously announced, the Company implemented a dual-track drug product manufacturing strategy and eng...

Read More
news image

Business Insights

ON DEMAND PHARMACEUTICALS ANNOUNCES PREFERRED SUPPLIER RELATIONSHIP WITH AZZUR GROUP

On Demand Pharmaceuticals, Azzur Group | June 02, 2022

On Demand Pharmaceuticals, Inc. an innovative technology company transforming the way medicines are made, announced that it has signed a Preferred Supplier agreement with Azzur Group through 2024. The transformation of ODP's Rockville Headquarters into a State-of-the-Art cGMP Medicine Manufacturing facility began with Azzur in the fall of 2020. Azzur collaborated in designing ODP's GMP Roadmap and helped develop the strategy and execution plan for ushering in this latest a...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us